<DOC>
	<DOC>NCT00383578</DOC>
	<brief_summary>This study is designed to demonstrate the efficacy and safety of vildagliptin compared to metformin in elderly drug naive patients with type 2 diabetes</brief_summary>
	<brief_title>Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age from 65 years to the upper age limit recommended by local prescribing information for metformin Drug naive patients with type 2 diabetes. Body mass index (BMI) in the range of 2240 kg/m2. HbA1c in the range of 7 to 9% inclusive FPG &lt;270 mg/dL (15 mmol/L) A history of type 1 diabetes Evidence of significant diabetic complications Treatment with insulin or any other oral antidiabetic agents Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>hemoglobin A1c</keyword>
	<keyword>metformin</keyword>
</DOC>